Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05610072 · ClinicalTrials.gov registry record · Early Phase 1
Behavioral Effects of Drugs (Inpatient): 43 (Opioids, Cocaine, n-Acetylcysteine)
A Early Phase 1 study of Opioid Use Disorder and Cocaine Use Disorder, sponsored by William Stoops.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 24
- Enrollment target
- 2
- Study locations
NCT05610072 is a Early Phase 1 study of Opioid Use Disorder and Cocaine Use Disorder that is actively recruiting participants, run by William Stoops. The registered enrollment target is 24 participants, below the 4,656-participant average among 257 other Opioid Use Disorder trials with a reported enrollment target (99% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT05610072, a Early Phase 1 study of Opioid Use Disorder and Cocaine Use Disorder, is actively recruiting participants, sponsored by William Stoops.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 24 participants
- Enrollment target
- 2
- Study locations
Study Summary
The overarching hypotheses of this protocol are that (1) persistent brain glutamate changes induced by chronic opioid use will exacerbate use of cocaine during opioid physical dependence and withdrawal and (2) n-acetylcysteine (NAC) will ameliorate glutamatergic dysregulation, and thus will reduce both opioid and cocaine demand. These hypotheses will be tested with two specific aims. Specific Aim 1. Determine the reinforcing effects of cocaine in individuals with comorbid opioid and cocaine use disorder with physiological dependence on opioids during NAC maintenance. All subjects will be maintained on oral hydromorphone. They will also be randomly assigned to receive placebo or oral NAC (2.4 g/day), stratified by sex. After dose stabilization, experimental sessions will be conducted in which subjects complete hypothetical cocaine purchase tasks during opioid maintenance and opioid withdrawal. The hypotheses are: 1) cocaine purchasing will be greater during opioid withdrawal and 2) NAC maintenance will attenuate cocaine purchasing across opioid maintenance and withdrawal periods. Specific Aim 2. Evaluate glutamate functionality during periods of opioid maintenance and withdrawal in individuals with comorbid opioid and cocaine use disorder and physiological dependence on opioids during NAC maintenance. Subjects will undergo magnetic resonance spectroscopy to evaluate brain glutamate changes as a function of opioid maintenance/withdrawal state and NAC maintenance. The hypotheses are: 1) glutamate levels will be elevated during opioid withdrawal and 2) NAC maintenance will ameliorate elevated glutamate levels.
Conditions Studied
Interventions
- DRUG Hydromorphone
- DRUG n-acetylcysteine
- DRUG Placebo n-acetylcystine
- DRUG Placebo hydromorphone
Study Locations (2)
Kentucky
- University of Kentucky Laboratory of Human Behavioral Pharmacology - Lexington
- University of Kentucky Department of Behavioral Science - Lexington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2022-12-15 |
| Est. Completion | 2026-12-31 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05610072
The ClinicalTrials.gov registry entry for NCT05610072 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,656-participant average among 257 other Opioid Use Disorder trials with a reported enrollment target (99% lower). The listed sponsor is William Stoops, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Opioid Use Disorder appearing as the primary indexed condition, and to 4 interventions - of which Hydromorphone is the first listed.
NCT05610072 reports 2 study locations spanning 1 distinct geographic area - top geographies include Kentucky.
Frequently Asked Questions
What is clinical trial NCT05610072 about?
NCT05610072 is a clinical study titled "Behavioral Effects of Drugs (Inpatient): 43 (Opioids, Cocaine, n-Acetylcysteine)". The overarching hypotheses of this protocol are that (1) persistent brain glutamate changes induced by chronic opioid use will exacerbate use of cocaine during opioid physical dependence and withdrawal and (2) n-acetylcysteine (NAC) will ameliorate glutamatergic dysregulation, and thus will reduce b...
What is the current status of trial NCT05610072?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 24 participants. The study started on 2022-12-15. Estimated completion is 2026-12-31.
What conditions does trial NCT05610072 study?
This clinical trial studies the following conditions: Opioid Use Disorder, Cocaine Use Disorder, Stimulant Use Disorder.
What interventions are being tested in trial NCT05610072?
The interventions under investigation include: Hydromorphone (DRUG), n-acetylcysteine (DRUG), Placebo n-acetylcystine (DRUG), Placebo hydromorphone (DRUG).
Who is sponsoring clinical trial NCT05610072?
This trial is sponsored by William Stoops, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05610072 being conducted?
This trial has 2 study locations across Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Opioid Use Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Clinical Trial Comparing Buprenorphine Formulations for High Potency Synthetic Opioid Use
RECRUITING · Early Phase 1
-
Cannabidiol in Opioid Use Disorder and Chronic Pain
RECRUITING · Early Phase 1
-
Open Trial of Technology-Enhanced Behavioral Intervention for Buprenorphine Retention in Pregnant and Postpartum People
ACTIVE NOT RECRUITING · Early Phase 1
-
Enhancing Prospective Thinking in Early Recovery (PARK)
COMPLETED · Early Phase 1
-
Opioid Treatment Program (OTP)-Pharmacy Collaboration for Methadone Maintenance Treatment
COMPLETED · Early Phase 1
-
Sustaining Recovery for People on Opioid Agonist Treatment With Conversational Agents
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.